Objective:To explore the clinical efficacy and safety of Nirmatrelvir/Ritonavir in retreatment for patients with recurrence of coronavirus disease 2019 (COVID-19).Methods:The COVID-19 patients hospitalized in Beijing Ditan Hospital, Capital Medical University and received Nirmatrelvir/Ritonavir therapy from April 17 to June 17 2022 were investigated and the clinical data were analyzed.Results:The retreatment with Nirmatrelvir/Ritonavir for the patients with recurrence of COVID-19 remained effective. The median value of time from the start of retreatment to negative conversion of nucleic acid was 8 (7-10) days. None of the patients showed adverse drug reaction.Conclusions:No drug-related adverse reaction was observed within the treatment course of Nirmatrelvir/Ritonavir and the therapy may be beneficial to shorten hospitalization and quarantine.

2012年10月由《中国防痨杂志》与《结核病与肺部健康杂志》编委会主办的首届"骨关节结核临床诊断与治疗进展及其规范化专题研讨会"在黄山市召开。会议汇聚了结核病防治、骨科、儿科、影像学界,以及结核病基础研究等诸多领域的知名学者、专家教授,就目前国内骨关节结核诊疗领域的一系列问题均做了深入的探讨,并对所存在问题进行沟通和分析,取得一定共识。近10余年,骨科技术尤其是脊柱外科技术突飞猛进发展的进程,加之种种问题的凸显带来的骨结核发病率上升,这为骨关节结核的规范化诊断和治疗带来了许多新问题、新思路。之前,关于骨关节结核诊疗的问题,《中国脊柱脊髓杂志》主导召开过数届研讨会,但主要局限于骨科领域。本届会议的亮点在于切入专题清晰准确——骨关节结核,同时有上述各领域的专家参与。使许多在单一专业领域内看起来比较抽象及遥远的问题获得化解,变得容易达成一致,为日后顺利解决某些分歧问题提供了契机,以及可供参考的模式与平台。这也符合了当前医学界多学科、多中心协作搞科研课题,相得益彰解决问题的循证医学潮流;为造福人民、发展健康事业,以及拓展预防控制、临床诊治骨关节结核专业工作者的视野和启迪学术思想起到了很好的推动作用。但本共识可能存在一些不足,甚至还有一些问题存在,希望各位专家同行多提建设性的意见或建议,共同改进,共同发展。